Synonyms: A-301 | ATI-50002 | ATI-502
Compound class:
Synthetic organic
Comment: The chemical structure that was submitted to the WHO for the INN ifidancitinib matches one of the that are claimed as Janus kinase (JAK) inhibitors in Rigel Pharmaceuticals' patent WO2012015972A1 [1]. Structurally ifidancitinib is identical to fosifidancitinib (fosifidancitinib) but without the phosphate group. The closest structural match in the patent is example I-221 but this has deuterium iotopes replacing some of the hydrogens on methylanilino group. This compound has been matched to ATI-502 which was developed as a topical agent for dermatological applications.
|
|
Classification | |
Compound class | Synthetic organic |
IUPAC Name |
5-[[2-(4-fluoro-3-methoxy-5-methylanilino)-5-methylpyrimidin-4-yl]amino]-3H-1,3-benzoxazol-2-one |
International Nonproprietary Names | |
INN number | INN |
11232 | ifidancitinib |
Synonyms |
A-301 | ATI-50002 | ATI-502 |
Database Links | |
CAS Registry No. | 1236667-40-5 (source: WHO INN record) |
ChEMBL Ligand | CHEMBL4594441 |
GtoPdb PubChem SID | 404859085 |
PubChem CID | 46851625 |
Search Google for chemical match using the InChIKey | OYFMQDVLFYKOPZ-UHFFFAOYSA-N |
Search Google for chemicals with the same backbone | OYFMQDVLFYKOPZ |
Search PubMed clinical trials | ifidancitinib |
Search PubMed titles | ifidancitinib |
Search PubMed titles/abstracts | ifidancitinib |
UniChem Compound Search for chemical match using the InChIKey | OYFMQDVLFYKOPZ-UHFFFAOYSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | OYFMQDVLFYKOPZ-UHFFFAOYSA-N |